Division of Medicine, Spedali Civili di Brescia, Montichiari, Brescia, Italy.
Department of Clinical and Experimental Sciences, University of Brescia, c/o 2a Medicina Spedali Civili Di Brescia, Piazza Spedali Civili 1, 25100, Brescia, Italy.
Intern Emerg Med. 2022 Oct;17(7):1941-1949. doi: 10.1007/s11739-022-03034-5. Epub 2022 Jul 9.
Coronavirus disease 2019 (COVID-19) represents a major health problem in terms of deaths and long-term sequelae. We conducted a retrospective cohort study at Montichiari Hospital (Brescia, Italy) to better understand the determinants of outcome in two different COVID-19 outbreaks. A total of 634 unvaccinated patients admitted from local emergency room to the Internal Medicine ward with a confirmed diagnosis of SARS-CoV-2 infection and a moderate-to-severe COVID-19 were included in the study. A group of 260 consecutive patients during SARS-CoV-2 first wave (from February to May 2020) and 374 consecutive patients during SARS-CoV-2 2nd/3rd wave (from October 2020 to May 2021) were considered. Demographic data were not significantly different between waves, except a lower prevalence of female sex during first wave. Mortality was significantly higher during the 1 wave than in the following periods (24.2% vs. 11%; p < 0.001). Time from symptoms onset to hospital admission was longer during first wave (8 ± 6 vs. 6 ± 4 days; p < 0.001), while in-hospital staying was significantly shorter (10 ± 14 vs. 15 ± 11 days; p < 0.001). Other significant differences were a larger use of corticosteroids and low-molecular weight heparin as well less antibiotic prescription during the second wave. Respiratory, bio-humoral and X-ray scores were significantly poorer at the time of admission in first-wave patients. After a multivariate regression analysis, C-reactive protein and procalcitonin values, % fraction of inspired oxygen on admission to the Internal Medicine ward and length of hospital stay and duration of symptoms were the strongest predictors of outcome. Concomitant anti-hypertensive treatment (including ACE-inhibitors and angiotensin-receptor blockers) did not affect the outcome. In conclusion, our data suggest that earlier diagnosis, timely hospital admission and rational use of the therapeutic options reduced the systemic inflammatory response and were associated to a better outcome during the 2nd/3rd wave.
新型冠状病毒病 2019(COVID-19)是一个重大的健康问题,涉及死亡和长期后遗症。我们在蒙蒂基亚里医院(意大利布雷西亚)进行了一项回顾性队列研究,以更好地了解两次不同 COVID-19 疫情中结局的决定因素。共有 634 名未接种疫苗的患者因当地急诊室确诊 SARS-CoV-2 感染和中度至重度 COVID-19 而被收入内科病房。考虑了一组 260 名连续患者,他们在 SARS-CoV-2 第一波(2020 年 2 月至 5 月)期间,以及 374 名连续患者在 SARS-CoV-2 第二/第三波(2020 年 10 月至 2021 年 5 月)期间。波之间的人口统计学数据没有显著差异,除了第一波期间女性比例较低。第一波的死亡率明显高于随后的时期(24.2%比 11%;p<0.001)。从症状出现到入院的时间在第一波期间较长(8±6 天比 6±4 天;p<0.001),而住院时间明显缩短(10±14 天比 15±11 天;p<0.001)。第二波期间,皮质类固醇和低分子量肝素的使用量以及抗生素的处方量也显著减少。第一波患者入院时呼吸、生物体液和 X 射线评分明显较差。在多变量回归分析后,C 反应蛋白和降钙素值、内科病房入院时吸入氧的百分比、住院时间和症状持续时间是结局的最强预测因子。同时进行的降压治疗(包括 ACE 抑制剂和血管紧张素受体阻滞剂)并不影响结局。总之,我们的数据表明,早期诊断、及时入院和合理使用治疗选择可减轻全身炎症反应,与第二/第三波期间的良好结局相关。